Farmacología cardiovascular: acceso abierto

Abstracto

Cystatin C in patients with coronary artery disease

Mohamed Wasfy Mohamed

Statement of the Problem: Cystatin C, first and foremost known as a marker of renal function and considered a better marker of glomerular filtration rate (GFR) than serum creatinine, has been suggested as a possible independent biomarker of cardiovascular disease (CVD). The purpose of this study is toassess the relation between level of serum Cystatin C and severity of coronary artery disease (CAD) in patients without chronic kidney disease (CKD). Methodology & Theoretical Orientation: In this cross-sectional study, we included 80 patients with CAD divided in two groups (group I with acute coronary artery disease and group II with chronic stable coronary artery disease) 40 patients each and acquired their demographic characteristics, medical histories, and listings of the concurrent medications they were taking. All patients with CAD underwent ECG, echocardiography, coronary angiography, serum Cystatin C level, cardiac enzymes and other routine laboratory tests.

Findings: As regard demographic data and comorbidities there was no significant difference between the two groups as regard gender, diabetes mellitus, hypertension or smoking. Also, As regard level of serum Cystatin C, the mean and SD in 1 vessel affection was 0.92±0.07 while in 2 vessels affection was 1.07±0.13 and 3 vessels affection was 1.41±0.05 with (P< 0.01). Finally, there was a highly significant difference as regard Cystatin C level with mean and SD 1.21±0.18 in ST-segment elevation MI while mean and SD was 0.96±0.09 in Non ST-segment MI or unstable angina with (P< 0.01).

There was a statistically significant correlation between level of Cystatin C and severity of CAD (p < 0.05)

Conclusions and Significance: Serum cystatin C has a significant effect on the severity of coronary artery disease (CAD) , being higher in patients with 3 vessels disease and severe CAD.